An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of IXAZOMIB (MLN9708) Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain Amyloidosis Who Require Further Treatment
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Ixazomib (Primary)
- Indications Amyloidosis
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 13 Mar 2017 Results (n=755) of pooled analysis of (C16001,C16002,C16003,C16004,C16005,C16007,C16008,C16010,C16013,TB-MC010034) ten studies assessing pharmacokinetic analysis of Ixazomib published in the Clinical Pharmacokinetics.
- 09 Mar 2017 Planned End Date changed from 1 Jun 2015 to 1 Dec 2017.
- 31 Mar 2015 Planned End Date changed from 1 Feb 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov